EGFR S784F

CI-VAR-00004127Explore in graph →ENST00000275493.2:c.2351C>TCIViC 1182

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
EGFR S784F	Erlotinib	Predictive	C	Supports Resistance	—	submitted	EID4469 In a pulmonary undifferentiated non-small cell lung cancer patient harboring EGFR S784F mutation, EGFR S784F was reported to be resistant to erlotinib treatment. The patient was initially treated with… (full text at CIViC) PMID 21841502 · De Pas et al., 2011 · Open in CIViC	civic
EGFR S784F	Gefitinib	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID4235 In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have S784F mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm2
EGFR S784F	Erlotinib + GefitinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5822 EGFR S784F was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic
EGFR S784F	Multikinase Inhibitor AEE788	Predictive	D	Supports Sensitivity Response	2	submitted	EID5823 EGFR S784F was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic